RedHill Biopharma Reports Second Quarter 2021 Financial Results and Operational Highlights
- Written by PR Newswire Asia - Daily Bulletin Au RSS
- Achieved record quarterly revenues of $21.5 million for Q2/2021, 4.5% increase from Q1/2021 despite challenging market conditions; Cash balance1 of approximately $71.5 million as of June 30, 2021
- Record Talicia® quarterly prescription volume up more than 10%; Movantik® quarterly new prescriptions up 5.6%; Talicia and Movantik coverage...